[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT05756985":3,"trial-entities:NCT05756985":94,"trial-summary:NCT05756985":97},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":22,"study_type":24,"primary_purpose":17,"phases":25,"enrollment_info":26,"interventions":29,"primary_outcomes":35,"secondary_outcomes":40,"sex":41,"minimum_age":42,"maximum_age":17,"healthy_volunteers":15,"eligibility_criteria":43,"std_ages":47,"locations":50,"central_contacts":70,"overall_officials":73,"references":76,"see_also_links":90},"NCT05756985","2022-SPEC-AHL-001","Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue","Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue (PRESERVE GBM)","RECRUITING","2029-01","2026-01","2026-02-04","2024-12-11","Baptist Health South Florida","OTHER",false,"To collect and preserve glioblastoma tissue during standard of care tumor resection surgery and blood for future molecular and genetic testing. Tissue for research will be collected from three different regions within the same tumor to study how these regions differ in their structure, DNA, and RNA and also to compare the data obtained from this testing to imaging data found in the medical record. The goal of this study is to help us better understand what the glioblastoma tumor tissue looks like and how it functions. This understanding can lead to new therapies for the treatment of glioblastoma in the future.",null,[19,20,21],"Glioblastoma","Glioblastoma Multiforme","Gliosarcoma",[23],"specimen banking","OBSERVATIONAL",[],{"count":27,"type":28},120,"ESTIMATED",[30],{"type":31,"name":32,"description":33,"armGroupLabels":34},"PROCEDURE","Specimen Collection","Collect and preserve glioblastoma tissue for exploratory analyses to generate hypotheses for future studies.",[19],[36],{"measure":37,"description":38,"timeFrame":39},"Number of glioblastoma (GBM) samples for analysis","Total number of GBM samples collected and preserved for analysis","2 years",[],"ALL","18 Years",{"inclusion":44,"exclusion":45,"raw_text":46},[],[],"Inclusion Criteria:\n\n1. Have the appearance of high-grade glioma on magnetic resonance (MR) imaging if allowed to consent and will undergo the procedure if the frozen is consistent with glioblastoma or gliosarcoma OR Patients with a history of histologically confirmed diagnosis of World Health Organization Grade glioblastoma or gliosarcoma that are undergoing repeat resection of a recurrent tumor as identified on preoperative MR imaging\n2. Aged ≥ 18 years old\n3. Contrast-enhancing tumor volume of at least 10 cc on the preoperative, volumetric MRI within 1 month prior to surgery\n4. Provision of signed and dated informed consent form by participant or legally authorized representative (LAR), if applicable\n\nExclusion Criteria:\n\n1\\. Has a history or current evidence of any medical condition, therapy, or laboratory abnormality that might confound the results of the study or is not in the best interest of the participant, in the opinion of the treating investigator.",[48,49],"ADULT","OLDER_ADULT",[51],{"facility":52,"status":8,"city":53,"state":54,"zip":55,"country":56,"contacts":57,"geoPoint":67},"Miami Cancer Institute at Baptist Health, Inc.","Miami","Florida","33176","United States",[58,63],{"name":59,"role":60,"phone":61,"email":62},"Manmeet S Ahluwalia, M.D.","CONTACT","786-596-2000","manmeeta@baptisthealth.net",{"name":64,"role":60,"phone":65,"email":66},"Michael McDermott, M.D.","(786) 596-2000","MWMCD@baptisthealth.net",{"lat":68,"lon":69},25.77427,-80.19366,[71,72],{"name":59,"role":60,"phone":65,"email":62},{"name":64,"role":60,"phone":65,"email":66},[74],{"name":59,"affiliation":52,"role":75},"PRINCIPAL_INVESTIGATOR",[77,81,84,87],{"pmid":78,"type":79,"citation":80},"29432615","BACKGROUND","GLASS Consortium. Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium. Neuro Oncol. 2018 Jun 18;20(7):873-884. doi: 10.1093\u002Fneuonc\u002Fnoy020.",{"pmid":82,"type":79,"citation":83},"25608559","Kumar A, Boyle EA, Tokita M, Mikheev AM, Sanger MC, Girard E, Silber JR, Gonzalez-Cuyar LF, Hiatt JB, Adey A, Lee C, Kitzman JO, Born DE, Silbergeld DL, Olson JM, Rostomily RC, Shendure J. Deep sequencing of multiple regions of glial tumors reveals spatial heterogeneity for mutations in clinically relevant genes. Genome Biol. 2014 Dec 3;15(12):530. doi: 10.1186\u002Fs13059-014-0530-z.",{"pmid":85,"type":79,"citation":86},"28263318","Lee JK, Wang J, Sa JK, Ladewig E, Lee HO, Lee IH, Kang HJ, Rosenbloom DS, Camara PG, Liu Z, van Nieuwenhuizen P, Jung SW, Choi SW, Kim J, Chen A, Kim KT, Shin S, Seo YJ, Oh JM, Shin YJ, Park CK, Kong DS, Seol HJ, Blumberg A, Lee JI, Iavarone A, Park WY, Rabadan R, Nam DH. Spatiotemporal genomic architecture informs precision oncology in glioblastoma. Nat Genet. 2017 Apr;49(4):594-599. doi: 10.1038\u002Fng.3806. Epub 2017 Mar 6.",{"pmid":88,"type":79,"citation":89},"27778090","Prasanna P, Patel J, Partovi S, Madabhushi A, Tiwari P. Radiomic features from the peritumoral brain parenchyma on treatment-naive multi-parametric MR imaging predict long versus short-term survival in glioblastoma multiforme: Preliminary findings. Eur Radiol. 2017 Oct;27(10):4188-4197. doi: 10.1007\u002Fs00330-016-4637-3. Epub 2016 Oct 24.",[91],{"label":92,"url":93},"Miami Cancer Institute","http:\u002F\u002Fcancer.baptisthealth.net",{"nct_id":4,"conditions":95,"biomarkers":96},[19,21],[],{"nct_id":4,"found":98,"summary":99,"prompt_version":109},true,{"design":100,"status":101,"heading":102,"summary":103,"follow_up":104,"word_count":105,"commitments":106,"compensation":107,"drugs_mentioned":108},"This is an observational study, meaning researchers will collect information without giving new treatments. It plans to enroll 120 participants.","completed","Understanding Glioblastoma Through Tissue Preservation","This study aims to better understand glioblastoma (a type of aggressive brain cancer) by collecting and preserving tumor tissue during standard surgery. Researchers will collect tissue from different parts of the same tumor, as well as blood, for future molecular and genetic testing. They will compare these findings with imaging data from your medical records. The goal is to learn more about how glioblastoma tissue looks and functions, which could lead to new treatments. You may be able to join if you have high-grade glioma (a type of brain tumor) on an MRI scan and are having surgery, or if you have a confirmed diagnosis of glioblastoma or gliosarcoma and are having surgery for a recurring tumor. The study plans to enroll 120 participants, and its current status is unclear.","The study aims to collect samples for analysis over 2 years, but it's not specified how long individual participants are followed.",130,"You would undergo standard of care tumor resection surgery. During this surgery, glioblastoma tissue and blood will be collected for research.","Not stated in the trial record.",[],"v2"]